FDA and EMA accept regulatory submissions for UCB’s bimekizumab
UCB is seeking approval for treatment in moderate-to-severe plaque psoriasis
Read MoreUCB is seeking approval for treatment in moderate-to-severe plaque psoriasis
Read MoreApp will automatically alert users when they come into close contact with someone with the virus
Read MoreEuropean Medicines Agency grants designation based on phase I/II data
Read MoreThe Leeds Dementia Pathfinder project supported patients and carers with tech devices
Read MoreStudy detected Nonalcoholic Fatty Liver Disease and Nonalcoholic steatohepatitis
Read MorePharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
